GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Sino Biopharmaceutical (FRA:SMZ1) Future 3-5Y EPS without NRI Growth Rate : 22.74 (As of Apr. 16, 2025)


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Sino Biopharmaceutical's Future 3-5Y EPS without NRI Growth Rate is 22.74.

Competitive Comparison of Sino Biopharmaceutical's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Sino Biopharmaceutical's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Sino Biopharmaceutical  (FRA:SMZ1) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Sino Biopharmaceutical Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
HKSE:09926 HKSE:06990 HKSE:01801 HKSE:01530 HKSE:01877 HKSE:01548 HKSE:02269 HKSE:09995 HKSE:09969 HKSE:02696 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
SBHMY:USA SBMFF:USA 01177:Hong Kong SMZ1:Germany
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Website
https://www.sinobiopharm.com
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

No Headlines